[Recommendations for initial antiretroviral treatment in HIV-infected children. Update 2003]

Area of Science:

• Pediatric Infectious Diseases
• Clinical Pharmacology
• Immunology

Context:

• Highly active antiretroviral therapy (HAART) has transformed outcomes for children with HIV, drastically reducing AIDS progression and mortality.
• Despite HAART's success, challenges persist, including the inability to eradicate the virus and the risk of chronic adverse effects, particularly metabolic complications.
• Individual patient factors complicate treatment standardization, necessitating careful consideration of age, drug tolerance, adherence, and social determinants.

Purpose:

• To provide an updated set of recommendations for the initial therapy of HIV-infected children.
• To balance the urgency of initiating treatment to prevent immunologic deterioration with the need to minimize long-term adverse effects.
• To adapt international guidelines and incorporate clinical experience for pediatric HIV management.

Summary:

• HAART has dramatically improved survival and quality of life in HIV-infected children, achieving latent infection rather than eradication.
• Chronic HAART use presents significant challenges, notably metabolic complications, and treatment initiation is complex due to drug regimens and patient-specific factors.
• Current recommendations aim to guide clinicians in balancing timely treatment initiation with the mitigation of long-term adverse effects in pediatric HIV care.

Impact:

• Improved clinical decision-making for initiating and managing antiretroviral therapy in children living with HIV.
• Potential reduction in long-term adverse effects associated with chronic HAART use in pediatric populations.
• Enhanced quality of life and long-term health outcomes for children infected with HIV through optimized treatment strategies.